Clinical Trials List
2026-07-01 - 2029-05-31
Phase III
Not yet recruiting4
Recruiting2
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/08/25
Investigators and Locations
Co-Principal Investigator
- 鄭智銘 Division of Psychiatry
- 鄭佳洵 Division of Psychiatry
- Ya-Mei Bai Division of Psychiatry
- W. C. LIN Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Yu-Jui Huang Division of Psychiatry
- 胡瑞元 Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 沈信衡 Division of Psychiatry
- Mao-Hsiu Hua Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 許茵茵 Division of Psychiatry
- 黃伯穎 Division of Psychiatry
- mei feng Huang Division of Psychiatry
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
鼻用噴液劑
Active Ingredient
Placebo
Dosage Form
404
Dosage
Endpoints
Inclution Criteria
Participant must meet the diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single episode MDD, the duration of the episode must be greater than or equal to [>=] 12 months) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the mini international neuropsychiatric interview (MINI) as the primary diagnosis. Participant must have had the first onset of depression prior to 55 years of age
Participant must have had nonresponse (less than or equal to [<=] 25 percent [%] improvement) to >=2 oral antidepressant treatments in the current episode of depression, assessed using the massachusetts general hospital-antidepressant treatment response questionnaire (MGH-ATRQ), and confirmed by documented records (for example, medical/pharmacy/prescription records or a letter from a treating physician)
The participant's current major depressive episode, depression symptom severity, and antidepressant treatment response in the current depressive episode, must be confirmed by the state versus trait, assessability, face validity, ecological validity, rule of three P's (SAFER) Interview
Participant must be comfortable with self-administration of nasal spray medication and be able to follow the nasal spray administration instructions provided
A female participant of childbearing potential must have a negative highly sensitive serum (β-human chorionic gonadotropin [β-hCG]) at the start of screening and a negative urine pregnancy test must be obtained before the first dose of study drug on Day 1, prior to randomization
Exclusion Criteria
The participant has used ketamine/esketamine (lifetime)
The participant's depressive symptoms have demonstrated nonresponse in the current major depressive episode to an adequate course of treatment with electroconvulsive therapy (ECT), defined as at least 7 treatments with unilateral/bilateral ECT, or to adequate course of treatment with transcranial magnetic stimulation (TMS), defined as at least 4 weeks of treatment with 5 sessions per week
Participant has received vagal nerve stimulation (VNS) or deep brain stimulation (DBS) in the current episode of depression
Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase, per the investigator's clinical judgment or based on the columbia suicide severity rating scale (C-SSRS), corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, or a history of suicidal behavior within the past year prior to the start of the screening phase. Participants reporting suicidal ideation with intent to act or suicidal behavior prior to the start of the double-blind treatment phase should be excluded
Participant has a history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before the start of the screening phase. a. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
Participant has a current or history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
348 participants
